跳至主要内容
临床试验/NCT05058638
NCT05058638招募中2 期

Evaluation of Halitosis Using a Multi-Mineral Approach (Aquamin®)

University of Michigan2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2022年8月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
25
试验地点
2
主要终点
Halitosis Associated Life-quality Test (HALT) questionnaire (modified)

研究概览

简要总结

The purpose of this study is to assess whether Aquamin®, a multi-mineral natural product from red marine algae, can help reduce halitosis when taken for 90 days.

详细描述

This is a sub-study to the ongoing clinical trial entitled: Aquamin®, a multi-mineral natural product from red marine algae, as an adjuvant intervention for mild ulcerative colitis and ulcerative colitis in remission (HUM00156676) NCT# NCT03869905.

However, the Food and Drug Administration (FDA) indicated that no Investigational New Drug Application (IND) was required.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must be able to give written informed consent
  • Willing to follow study procedures of no eating, drinking, toothbrushing, smoking or using mouth rinse 60 minutes before study visits
  • Have stable oral health
  • Self-reported halitosis
  • A negative pregnancy test for pre-menopausal women with intact female reproductive organs, and the subject must agree to use appropriate birth control over the study period.

排除标准

  • Pregnant or lactating women
  • Participating in any other interventional trials using an investigational drug
  • Diagnosed with any stomach or intestinal bleeding disorders (gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin-secreting tumors) or active gastric/duodenal ulcers - peptic ulcer disease (in last 3 months) or with severe symptoms of ulcerative colitis or Crohn's disease
  • Any gastrointestinal or colonic malignancy; kidney disease, including kidney "stones" or hypercalcemia
  • Coagulopathy/hereditary hemorrhagic disorders/or receiving therapeutic doses of Coumadin or heparin
  • Have any severe oral condition that, in the opinion of the oral healthcare provide might impact the results of the study if the condition is treated
  • Have been treated for oral cancer within the past year
  • Taking any of the following within 30 days (will be eligible after completing 30 days of washout period):
  • Calcium; Vitamin D, including multivitamins that have low amounts of calcium/Vitamin D supplements; Oral steroids; Non-steroidal anti-inflammatory medications (NSAIDS); Antibiotics.

研究组 & 干预措施

Aquamin®

Experimental

干预措施: Aquamin (Drug)

结局指标

主要结局

Halitosis Associated Life-quality Test (HALT) questionnaire (modified)

时间窗: 90 days (post-intervention)

Following the intervention, participants will answer questions regarding if their bad breath has improved over the course of the study compared to the starting point. The scores will be from 0 (no issue) - 5 (worst possible issue) for each question.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Muhammad N Aslam, MD

Associate Research Scientist

University of Michigan

研究点 (2)

Loading locations...

相似试验